Stock Research for FOLD

FOLD
Current Price

$15.1350


Latest Update: 2018-02-21 16:00:00

High
$ 15.1400
Low
$ 15.1100
Close
$ 15.1100
Volume
61182
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

FOLD Stock Chart & Research Data

The FOLD chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the FOLD chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


FOLD Due diligence Resources & Stock Charts

The FOLD stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View FOLD Detailed Price Forecast - CNN Money CNN View FOLD Detailed Summary - Google Finance
Yahoo View FOLD Detailed Summary - Yahoo! Finance Zacks View FOLD Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View FOLD Trends & Analysis - Trade-Ideas Barrons View FOLD Major Holders - Barrons
NASDAQ View FOLD Call Transcripts - NASDAQ Seeking View FOLD Breaking News & Analysis - Seeking Alpha
Spotlight View FOLD Annual Report - CompanySpotlight.com OTC Report View FOLD OTC Short Report - OTCShortReport.com
TradeKing View FOLD Fundamentals - TradeKing Charts View FOLD SEC Filings - Bar Chart
WSJ View Historical Prices for FOLD - The WSJ Morningstar View Performance/Total Return for FOLD - Morningstar
MarketWatch View the Analyst Estimates for FOLD - MarketWatch CNBC View the Earnings History for FOLD - CNBC
StockMarketWatch View the FOLD Earnings - StockMarketWatch MacroAxis View FOLD Buy or Sell Recommendations - MacroAxis
Bullish View the FOLD Bullish Patterns - American Bulls Short Pains View FOLD Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View FOLD Stock Mentions - StockTwits PennyStocks View FOLD Stock Mentions - PennyStockTweets
Twitter View FOLD Stock Mentions - Twitter Invest Hub View FOLD Investment Forum News - Investor Hub
Yahoo View FOLD Stock Mentions - Yahoo! Message Board Seeking Alpha View FOLD Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for FOLD - SECform4.com Insider Cow View Insider Transactions for FOLD - Insider Cow
CNBC View FOLD Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for FOLD - OTC Markets
Yahoo View Insider Transactions for FOLD - Yahoo! Finance NASDAQ View Institutional Holdings for FOLD - NASDAQ


Stock Charts

FinViz View FOLD Stock Insight & Charts - FinViz.com StockCharts View FOLD Investment Charts - StockCharts.com
BarChart View FOLD Stock Overview & Charts - BarChart Trading View View FOLD User Generated Charts - Trading View


Latest Financial News for FOLD

Amicus Therapeutics to Announce Full-Year 2017 Financial Results on February 28, 2018
Posted on Wednesday February 21, 2018

CRANBURY, N.J., Feb. 21, 2018-- Amicus Therapeutics today announced a conference call and live audio webcast on Wednesday, February 28, 2018 at 8:30 a.m. ET to discuss financial results for the full year ...


Amicus Therapeutics Prices Underwritten Offering of Common Stock
Posted on Thursday February 15, 2018

CRANBURY, N.J., Feb. 15, 2018-- Amicus Therapeutics today announced the pricing of an underwritten offering of 19,354,839 shares of its common stock at $15.50 per share. The gross proceeds from the offering ...


Amicus Therapeutics Announces Public Offering of Common Stock
Posted on Wednesday February 14, 2018

CRANBURY, N.J., Feb. 14, 2018-- Amicus Therapeutics today announced it has commenced a $250 million underwritten public offering of its common stock. Morgan Securities LLC and Goldman Sachs & Co. LLC are ...


Blog Exposure - FDA Accepts Amicus Therapeutics’ NDA for Migalastat for Treatment of Fabry Disease
Posted on Wednesday February 14, 2018

Stock Monitor: Immunomedics Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 14, 2018 / Active-Investors.com has just released a free research report on Amicus Therapeutics, Inc. (NASDAQ: FOLD ...


Traders Secrets on Amicus Therapeutics, Inc. (FOLD), Globalstar, Inc. (GSAT)
StockNewsJournal - 4 hours ago
ROI deals with the invested cash in the company and the return the investor realize on that money based on the net profit of the business.
Comparing Sanchez Energy Corporation (SN) and Amicus Therapeutics, Inc. (FOLD) - StockNewsGazette
Leerink Swann Weighs in on Amicus Therapeutics, Inc.'s Q1 2018 Earnings (FOLD) - StockNewsTimes

Amicus Therapeutics: What To Expect In 2018
Seeking Alpha - Jan 24, 2018
Amicus started the year near 52-week lows. The company announced in late 2016 that the FDA wanted another phase 3 study for Galafold, which effectively delayed the product's arrival to market by at least three years.
Amicus Therapeutics Inc. (FOLD) Soars 7.2% on January 23 - Equities.com

Amicus Therapeutics Announces Presentations and Posters at 14th Annual ...
GlobeNewswire (press release) - Jan 22, 2018
January 22, 2018 16:01 ET | Source: Amicus Therapeutics, Inc. CRANBURY, N.J., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today announced that two oral presentations and seven posters highlighting its development programs for ...

Amicus Therapeutics: Pompe Data Strengthens Bullish Thesis
Seeking Alpha - Feb 8, 2018
Pompe market opportunity appears attractive with 5,000 to 10,000 patients worldwide and 2016 global ERT sales reaching nearly $800 million.

Enter a stock symbol to view the stock details.